DCM
JAZZ icon

DGS Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

DGS Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$290K Buy
1,536
+5
+0.3% +$874 0.05% 413
2025
Q4 		$260K Buy
+1,531
New +$235K 0.04% 368

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

DGS Capital Management's JAZZ Position: Q1 2026 in Review

DGS Capital Management increased its Jazz Pharmaceuticals (JAZZ) stake by 0.33% in Q1 2026, buying an estimated $874 and bringing the position to 1,536 shares worth $290K. The position accounts for 0.05% of the portfolio, ranked #413.

DGS Capital Management first reported a position in JAZZ in Q4 2025 and has held it in 2 quarters since. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • DGS Capital Management held 1,536 shares of Jazz Pharmaceuticals worth $290K as of Q1 2026.
  • DGS Capital Management bought 5 Jazz Pharmaceuticals shares in Q1 2026, an estimated $874.
  • Jazz Pharmaceuticals made up 0.05% of DGS Capital Management's portfolio in Q1 2026, its #413 holding.
  • DGS Capital Management first reported a position in Jazz Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on DGS Capital Management's 13F filing for Q1 2026, filed 28 Apr 2026.